Neuroscience-focused startup BrainSight AI has raised $5 million in a pre-Series A funding round led by IAN Alpha Fund, with additional backing from IvyCap Ventures, Silver Needle, and existing investors. This Bengaluru-based startup, which previously received $925,000 from Pfizer and other supporters, plans to leverage the funds for strategic expansion across Tier I and Tier II cities in India, foraying into Africa and Southeast Asia, and advancing its U.S. market entry through FDA certification.
Founded in 2019 by CEO Laina Emmanuel, an ISB graduate, and CTO Rimjhim Agrawal, a PhD from NIMHANS, BrainSight AI integrates artificial intelligence and neuroscience to provide innovative solutions for diagnosing and treating brain disorders. The startup’s flagship offerings include Voxelbox, a machine-learning-powered fMRI processing engine, and Snowdrop, a patient-care app designed to enhance treatment adherence.
The startup collaborates with over 40 hospitals across India, focusing on neurosurgery and radiology, particularly for brain tumor cases. Through advanced neural mapping, BrainSight AI empowers surgeons to plan safer, more precise procedures while expanding its applications to neurological and psychiatric conditions.
By democratizing access to advanced neuroscience tools, BrainSight AI aspires to extend brain care traditionally available only at institutions like Harvard and Stanford to a global patient base. With its expanded R&D pipeline and emphasis on connectomics—the study of brain networks—the startup is set to transform neuro-oncological and neuropsychiatric care.
